Zynex Inc CEO Thomas Sandgaard joined Steve Darling from Proactive to share news the company has announced a major leadership transition as Steven Dyson has been appointed Chief Executive Officer, marking a pivotal moment for the medical technology company as it refines its strategic direction. Sandgaard, who founded Zynex in 1996 and has served as its CEO since inception, will now step back from daily operations but remain actively involved in the company’s future. He will continue in his role as Chairman of the Board and serve as Chair of the Technology Committee, ensuring continuity and innovation remain cornerstones of Zynex’s long-term strategy. Steven Dyson brings over 25 years of global experience in the medical technology and healthcare sectors. Most recently, he served in a senior leadership role at Apax Partners, a prominent private equity firm where he played a key role in acquiring, scaling, and divesting successful medtech and healthcare businesses. Dyson’s portfolio includes major names such as KCI, Rodenstock, Healthium Medtech, Unilabs, and Neuraxpharm, reflecting a deep understanding of how to drive performance across complex healthcare organizations. As Zynex aims to refocus its business strategy with a greater emphasis on a more optimized payer mix and improved profitability, Dyson’s leadership is expected to be transformative. His ability to execute strategic pivots and deliver sustainable value creation will be critical as the company seeks to reinvigorate its growth trajectory and expand its market presence in non-invasive pain management and diagnostic technologies. The appointment of Dyson signals Zynex’s commitment to evolving with the healthcare landscape, enhancing operational excellence, and capturing new market opportunities as the company enters its next phase of growth. #proactiveinvestors #zynexinc #nasdaq #zyxi #healthcare #ThomasSandgaard #CEOTransition #MedicalDevices #HealthcareLeadership #StevenDyson #ZynexInc #PainManagement #BusinessAnnouncement